Mobile Health AG has developed the medidux™ smartphone application (app) for this purpose, which is intended to be used alongside therapy. You can enter symptoms and well-being, document vital signs (e.g. blood pressure) and complete a simple cognitive test. Your doctor can view this data directly during the scheduled consultation hours / visits. With this study, we want to find out whether electronic data collection offers advantages for patients in terms of dealing with symptoms and can thus support therapy support.
Aim of the study
Mobile Health AG has developed the medidux™ smartphone application (app) for this purpose, which is intended to be used alongside therapy. You can enter symptoms and well-being, document vital signs (e.g. blood pressure) and complete a simple cognitive test. With this study, we want to find out whether electronic data collection offers advantages for patients in terms of dealing with symptoms and can thus support therapy support.
Who can take part?
HER2-positive breast cancer and chemotherapy in combination with HER2-targeted therapy (including tyrosine kinase inhibitors [TKI]) or therapy with an antibody-drug conjugate is planned.
Procedure
The app can be used for around 12 to a maximum of 16 weeks. There is no additional work involved apart from installing the app. Everything relevant to the study will take place during the consultation hours / visits scheduled for the regular treatment of your breast cancer.
Compensation
none
Original study name
Evaluation of the digital health application medidux™ in patients with HER2-positive breast cancer during chemotherapy in combination with a HER2-targeted therapy (including tyrosine kinase inhibitors [TKI]) or a therapy with a HER2-targeted therapy.
BASEC number
2022-D0021
Sponsors